Patient Square Capital’s C4 Therapeutics CCCC Stock Holding History

Patient Square Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.51M	Buy	+1,608,815	New	+$5.5M	1.16%	20

Other funds holding CCCC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Patient Square Capital's CCCC Position: Q2 2026 in Review

Patient Square Capital opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 1,608,815 shares worth $7.51M. The stake represents 1.16% of the portfolio and ranks #20 among its holdings.

63 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Patient Square Capital held 1,608,815 shares of C4 Therapeutics worth $7.51M as of Q2 2026.
C4 Therapeutics was a new Patient Square Capital position in Q2 2026.
C4 Therapeutics made up 1.16% of Patient Square Capital's portfolio in Q2 2026, its #20 holding.
63 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.